Your browser doesn't support javascript.
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
Ng, Dianna L; Goldgof, Gregory M; Shy, Brian R; Levine, Andrew G; Balcerek, Joanna; Bapat, Sagar P; Prostko, John; Rodgers, Mary; Coller, Kelly; Pearce, Sandra; Franz, Sergej; Du, Li; Stone, Mars; Pillai, Satish K; Sotomayor-Gonzalez, Alicia; Servellita, Venice; Martin, Claudia Sanchez San; Granados, Andrea; Glasner, Dustin R; Han, Lucy M; Truong, Kent; Akagi, Naomi; Nguyen, David N; Neumann, Neil M; Qazi, Daniel; Hsu, Elaine; Gu, Wei; Santos, Yale A; Custer, Brian; Green, Valerie; Williamson, Phillip; Hills, Nancy K; Lu, Chuanyi M; Whitman, Jeffrey D; Stramer, Susan L; Wang, Candace; Reyes, Kevin; Hakim, Jill M C; Sujishi, Kirk; Alazzeh, Fariba; Pham, Lori; Thornborrow, Edward; Oon, Ching-Ying; Miller, Steve; Kurtz, Theodore; Simmons, Graham; Hackett, John; Busch, Michael P; Chiu, Charles Y.
  • Ng DL; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Goldgof GM; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
  • Shy BR; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Levine AG; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Balcerek J; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Bapat SP; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Prostko J; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Rodgers M; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA.
  • Coller K; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA.
  • Pearce S; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA.
  • Franz S; Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA.
  • Du L; Vitalant Research Institute, San Francisco, CA, USA.
  • Stone M; Vitalant Research Institute, San Francisco, CA, USA.
  • Pillai SK; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Sotomayor-Gonzalez A; Vitalant Research Institute, San Francisco, CA, USA.
  • Servellita V; Vitalant Research Institute, San Francisco, CA, USA.
  • Martin CSS; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Granados A; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Glasner DR; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Han LM; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Truong K; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Akagi N; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Nguyen DN; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Neumann NM; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Qazi D; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Hsu E; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Gu W; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Santos YA; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
  • Custer B; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Green V; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
  • Williamson P; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Hills NK; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
  • Lu CM; Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, USA.
  • Whitman JD; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
  • Stramer SL; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
  • Wang C; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Reyes K; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Hakim JMC; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Sujishi K; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Alazzeh F; Vitalant Research Institute, San Francisco, CA, USA.
  • Pham L; Creative Testing Solutions, Tempe, AZ, USA.
  • Thornborrow E; Creative Testing Solutions, Tempe, AZ, USA.
  • Oon CY; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
  • Miller S; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
  • Kurtz T; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Simmons G; Laboratory Medicine Service, San Francisco VA Health Care System, San Francisco, CA, USA.
  • Hackett J; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Busch MP; American Red Cross, Gaithersburg, MD, USA.
  • Chiu CY; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Nat Commun ; 11(1): 4698, 2020 09 17.
Article in English | MEDLINE | ID: covidwho-780000
ABSTRACT
Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Betacoronavirus Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-18468-8

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Betacoronavirus Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-18468-8